PE20160904A1 - Combinacion triple para reduccion de presion intraocular - Google Patents
Combinacion triple para reduccion de presion intraocularInfo
- Publication number
- PE20160904A1 PE20160904A1 PE2016000624A PE2016000624A PE20160904A1 PE 20160904 A1 PE20160904 A1 PE 20160904A1 PE 2016000624 A PE2016000624 A PE 2016000624A PE 2016000624 A PE2016000624 A PE 2016000624A PE 20160904 A1 PE20160904 A1 PE 20160904A1
- Authority
- PE
- Peru
- Prior art keywords
- intraocular pressure
- pressure reduction
- triple combination
- sodium
- chloride
- Prior art date
Links
- 230000004410 intraocular pressure Effects 0.000 title abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 abstract 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 abstract 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 abstract 1
- 229960002470 bimatoprost Drugs 0.000 abstract 1
- 229960001724 brimonidine tartrate Drugs 0.000 abstract 1
- 229960002303 citric acid monohydrate Drugs 0.000 abstract 1
- 229940052354 dibasic sodium phosphate heptahydrate Drugs 0.000 abstract 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 229960002668 sodium chloride Drugs 0.000 abstract 1
- 229940083608 sodium hydroxide Drugs 0.000 abstract 1
- 229960005221 timolol maleate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica que contiene 0.01% p/v de bimatoprost, 0.15% p/v de tartrato de brimonidina y 0.68% p/v de maleato de timolol; dicha composicion contienen ademas fosfato de sodio dibasico heptahidratado, monohidrato de acido citrico, cloruro de sodio, hidroxido sodico y cloruro de benzalconio en un medio acuoso; siendo util para disminuir la presion intraocular (PIO) ocasionada por glaucoma y trabeculectomia post quirurgica
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28893609P | 2009-12-22 | 2009-12-22 | |
| US36174910P | 2010-07-06 | 2010-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160904A1 true PE20160904A1 (es) | 2016-09-16 |
Family
ID=43743470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000877A PE20121468A1 (es) | 2009-12-22 | 2010-12-21 | Combinacion triple para reduccion de presion intraocular |
| PE2016000624A PE20160904A1 (es) | 2009-12-22 | 2010-12-21 | Combinacion triple para reduccion de presion intraocular |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000877A PE20121468A1 (es) | 2009-12-22 | 2010-12-21 | Combinacion triple para reduccion de presion intraocular |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130116254A1 (es) |
| CN (1) | CN102695498A (es) |
| AR (1) | AR079696A1 (es) |
| BR (1) | BR112012017319A2 (es) |
| CL (1) | CL2012001736A1 (es) |
| CO (1) | CO6592061A2 (es) |
| CR (1) | CR20120360A (es) |
| EC (1) | ECSP12012033A (es) |
| GT (1) | GT201200213A (es) |
| IN (1) | IN2012DN06416A (es) |
| MX (1) | MX2012007397A (es) |
| NI (1) | NI201200112A (es) |
| PE (2) | PE20121468A1 (es) |
| TW (1) | TW201143773A (es) |
| WO (1) | WO2011087790A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| SI2598119T1 (sl) | 2010-07-29 | 2019-02-28 | Allergan, Inc. | Raztopine z brimodinom in timololom brez konzervansov |
| EP2841104A1 (en) * | 2012-04-24 | 2015-03-04 | Allergan, Inc. | Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
| KR20170129823A (ko) * | 2015-03-19 | 2017-11-27 | 알러간, 인코포레이티드 | 브리모니딘 및 티몰롤의 고정된 용량 조합 |
| US20210121534A1 (en) * | 2018-06-19 | 2021-04-29 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| US12064440B2 (en) * | 2022-03-21 | 2024-08-20 | Somerset Therapeutics, Llc | Ophthalmic gel compositions of bimatoprost and timolol and associated methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US4994274A (en) | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| US7851504B2 (en) * | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
-
2010
- 2010-12-21 CN CN2010800609772A patent/CN102695498A/zh active Pending
- 2010-12-21 PE PE2012000877A patent/PE20121468A1/es not_active Application Discontinuation
- 2010-12-21 US US13/698,182 patent/US20130116254A1/en not_active Abandoned
- 2010-12-21 BR BR112012017319A patent/BR112012017319A2/pt not_active Application Discontinuation
- 2010-12-21 PE PE2016000624A patent/PE20160904A1/es unknown
- 2010-12-21 WO PCT/US2010/061563 patent/WO2011087790A1/en active Application Filing
- 2010-12-21 MX MX2012007397A patent/MX2012007397A/es active IP Right Grant
- 2010-12-22 AR ARP100104881A patent/AR079696A1/es not_active Application Discontinuation
- 2010-12-22 TW TW099145385A patent/TW201143773A/zh unknown
-
2012
- 2012-06-22 NI NI201200112A patent/NI201200112A/es unknown
- 2012-06-22 GT GT201200213A patent/GT201200213A/es unknown
- 2012-06-22 CL CL2012001736A patent/CL2012001736A1/es unknown
- 2012-06-29 CR CR20120360A patent/CR20120360A/es unknown
- 2012-07-11 EC ECSP12012033 patent/ECSP12012033A/es unknown
- 2012-07-19 CO CO12122166A patent/CO6592061A2/es not_active Application Discontinuation
- 2012-07-20 IN IN6416DEN2012 patent/IN2012DN06416A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012017319A2 (pt) | 2016-04-19 |
| CR20120360A (es) | 2012-07-30 |
| PE20121468A1 (es) | 2012-10-28 |
| AR079696A1 (es) | 2012-02-15 |
| WO2011087790A1 (en) | 2011-07-21 |
| NI201200112A (es) | 2013-04-09 |
| MX2012007397A (es) | 2012-08-15 |
| CN102695498A (zh) | 2012-09-26 |
| US20130116254A1 (en) | 2013-05-09 |
| CL2012001736A1 (es) | 2012-10-12 |
| TW201143773A (en) | 2011-12-16 |
| CO6592061A2 (es) | 2013-01-02 |
| IN2012DN06416A (es) | 2015-10-09 |
| GT201200213A (es) | 2014-08-29 |
| ECSP12012033A (es) | 2012-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160904A1 (es) | Combinacion triple para reduccion de presion intraocular | |
| AU2006227757B2 (en) | Enhanced bimatoprost ophthalmic solution | |
| ES2542728T3 (es) | Composiciones farmacéuticas que tienen la biodisponibilidad deseable | |
| WO2013037479A8 (en) | Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
| RU2010142353A (ru) | Водные фармацевтические композиции, содержащие борат-полиольные комплексы | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| EA201290097A1 (ru) | Спиртовые композиции, имеющие пониженный риск возникновения ацетальдегидемии | |
| US20140088107A1 (en) | Ophthalmic preparation comprising a pgf2alpha analogue | |
| RS53085B (en) | SUSPENSIONS OF NANOPARTICLES CONTAINING CARBOXIVINILE POLYMER | |
| RU2013107744A (ru) | Растворы биматопроста и тимолола, не содержащие консервантов | |
| JP2014515383A5 (es) | ||
| PL431139A1 (pl) | Kompozycja farmaceutyczna bimatoprostu i tymololu | |
| US7960431B2 (en) | Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension | |
| AR047438A1 (es) | Sal amina de derivado de carboestirilo | |
| GEP20156301B (en) | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | |
| JP6150510B2 (ja) | 眼科用水性組成物 | |
| TW201542242A (zh) | 陰離子性軟式隱形眼鏡用眼科用組成物 | |
| MX2012005447A (es) | Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular. | |
| WO2013047373A1 (ja) | 亜塩素酸塩を含有する水性製剤 | |
| JP6628924B2 (ja) | 水性液剤 | |
| RU2012113380A (ru) | Офтальмологические композиции, содержащие дорзоламид, тимолол и бримонидин | |
| AU2011211356B2 (en) | Enhanced bimatoprost ophthalmic solution | |
| PE20080347A1 (es) | Solucion oftalmica de ciprofloxacina y dexametasona | |
| TW201517904A (zh) | 兩性離子性軟式隱形眼鏡用眼科用組成物 | |
| TW201534351A (zh) | 兩性離子性軟式隱形眼鏡用眼科用組成物 |